Fucoidan-loaded, neutrophil membrane-coated nanoparticles facilitate MRSA-accompanied wound healing

Treatment of methicillin-resistant Staphylococcus aureus (MRSA)-infected wounds remains an important clinical challenge. Current treatments using vancomycin usually result in high side effects with low treatment efficacy because of strong drug toxicity and weak targeting specificity. It is emergently needed to develop a novel antimicrobial agent and target drug delivery system. Herein, we developed anti-infection nanoparticles (LMM NPs) with autonomous targeting ability, loading low-molecular-weight fucoidan (LMWF) and coated by neutrophil membranes, and used for the therapy of MRSA-infected wounds. The LMWF molecules possess similar anti-MRSA effects as vancomycin but lower nephrotoxicity. Nanoparticles coated with the neutrophil membrane can escape immune recognition due to the retained cell membrane components and accumulate in the infection site. Furthermore, the MRSA-infected wound model confirms that the LMM NPs accumulate efficiently in MRSA-infected tissues and have good biocompatibility and excellent antibacterial ability in MRSA-infected wounds, which promote MRSA-accompanied wound healing. These novel infection-targeted LMWF-loaded NPs could be applied as a useful strategy for the targeted treatment of infection therapy. This will provide a meaningful reference to extend clinical treatment in MRSA infection of deep tissues.